Sunday, July 20, 2008
pehel.com
Home Latest News Pakistan World Science / Technology Sports Entertainment Health Business
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Source: Medical News Today E-Mail this News Story to a friend E-Mail this Story
Category: Health
Publication Date: Fri, 09 May 2008 00:00:00 PDT
News URL: http://www.medicalnewstoday.com/articles/106849.php
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase InhibitorEntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase 1 study of ENMD-2076 in advanced cancer patients. Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, and Dr.
Click here for full Story
http://www.medicalnewstoday.com/articles/106849.php
Bookmark this news story online:
Add Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to BlinkListAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to DeliciousAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to DiggAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to FarkAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to FurlAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to BlogarithmAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to MeneameAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to My Yahoo!Add Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to ReddItAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to ShadowsAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to SimpyAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to SpurlAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Sync2ItAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to MagnoliaAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to NewsVineAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Ask Jeeves
Add Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Raw SugarAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to DiigoAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to NetVouzAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Stumble UponAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to SegnaloAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Google BookmarksAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Microsoft LiveAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to BlogMarksAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to WinkAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to TechnoratiAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Feed Me LinksAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to LinkaGoGoAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to BlueDotAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Mister WongAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to TailRankAdd Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor to Yahoo Bookmarks

Comments

No comments found... be the first one to comment on this story :)

Post a Comment
Name:
   
E-Mail Address:
   
Website / Blog URL (optional):
   
Comments:
   
Security Code:
   
  
   By submitting these comments, you are agreeing to our Terms of Service
    
Latest News
Latest News World News Pakistan News Technology News Entertainment News Business News Sports News
bullet Association Between Serum Prostate-Specific Antigen Level, Liver Function Tests And Lipid Profile In Healthy Men
bullet Barriers To The Practice Of Evidence-Based Urology
bullet Impact Of Surgical Volume On The Rate Of Lymph Node Metastases In Patients Undergoing Radical Prostatectomy
bullet Comprehensive Clinic For Gastrointestinal Cancers Opens At Rush University Medical Center, USA
bullet Launch Of Zenith AAA Iliac Legs With Flex Stent Gapping Designed To Have Increased Flexibility And Improved Conformability
bullet Drexel University College Of Nursing Receives $1.4 MM Federal Grant To Spread Nursing Technology Expertise Nationally, USA
bullet A New-Generation Of Simpler Sensors For Detecting Disease-Causing Microbes And Toxins
bullet 'Snow Flea Antifreeze Protein' Could Help Improve Organ Preservation
bullet Killer Kevlar - Clothing That Shields From Germs
bullet The 1st Pan-American Congress On Aesthetic And Anti-Aging Medicine
bullet Michael J. Fox Foundation Awards $2.4 Million For Validation Of Nine Promising Therapeutic Targets For Parkinson's Disease
bullet Medical-Surgical Nurses Can Be Advocates For Family Presence During Resuscitation
bullet Nurses Can Help Patients By Taking A Stand Against Smoking
bullet Study Finds Temperature-Taking Methods Are Not Interchangeable
bullet Treating Depression Reduces Risk Of Heart Disease
bullet Elderly Falls Cut By 11 Percent With Education And Intervention
bullet China Can't Fully Fix Air Quality Problem For Olympics According To URI Researcher
bullet American Public Health Association Applauds New Report On Health Impacts Of Climate Change
bullet Sophie Suffers From A Rare Form Of Mitochondrial Disease That Has Made Her Muscles Extremely Weak, Website Launched
bullet California Academy Of Family Physicians Lauds Congress On Medicare Veto Override; Call On CA Legislators To Similarly Rescind Medi-Cal Cuts
bullet Pharmacy Educators Break Science's Boundaries At 2008 AACP/AFPC Annual Meeting And Seminars
bullet Premera Partners With American Cancer Society To Offer Tobacco Cessation Program - Highest Quit Rate For Employer-Based Programs In The Nation
bullet By 2012, Legitimate Generics Will Account For 20% Of Brazil's Pharmaceuticals And Healthcare Market
bullet ERBITUX® (Cetuximab) Receives Approval In Japan For Use In Advanced Colorectal Cancer
bullet FDA Special Protocol Assessment (SPA) For Expanded Indication Of LibiGel® In FSD For Female Sexual Dysfuntion
 
© 2007 Verge Systems